ライフサイエンスコーパス: walk test

1 or an increase of >50 meters on the 6-minute walk test).

2 walking impairment questionnaire, and 6-min walk test.

3 asure was change in walk time on a treadmill walk test.

4 ween neuropathy groups were observed for the walk test.

5 Key secondary endpoint included 6-min walk test.

6 p differences were observed for the 6-minute walk test.

7 oxygen consumption measurement, and a 6-min walk test.

8 dynamics, functional class, and the 6-minute walk test.

9 and less distance walked during the 6-Minute Walk Test.

10 SS), 9-hole peg test (HPT) and timed 25-foot walk test.

11 of follow-up, accompanied by improved 6-min walk test.

12 eadmill test, Timed-Stands Test, and 50-Foot Walk Test.

13 eadmill test, Timed-Stands Test, and 50-Foot Walk Test.

14 oxygen consumption during a 10-meter shuttle walk test.

15 ise capacity (E), measured by the six-minute-walk test.

16 ated to female gender, heart rate, and prior walk test.

17 aturation to 88% or less during the 6-minute walk test.

18 ional status was assessed using the 6-minute walk test.

19 physema, airway wall thickness, and 6-minute-walk test.

20 induce normal ambulation endurance in a 1-h walk test.

21 l hearing, respectively, during the 2-minute walk test.

22 (EDSS), Nine-Hole Peg Test and Timed 25-Foot Walk test.

23 2% arterial stiffness exam, and 77% 6-minute walk test.

24 h ILD who desaturate below 88% on a 6-minute walk test.

25 ks after surgery, measured with the 6-minute walk test.

26 lth questionnaires, and completed a 6-minute walk test.

27 diography, electrocardiography, and 6-minute walk test.

28 as assessed for 2 years using timed 20-meter walk tests.

29 ls at 3 months completed Incremental Shuttle Walk Tests.

30 the Timed Up and Go Test (TUG) and 10-Meter Walk Tests.

31 e assessed once and did not undergo 6-minute walk testing.

32 ly reduced error rate in a horizontal ladder-walking test.

33 a wide range of performance on this extended walking test.

34 affixed to the sternum and performed a 10-m walking test.

35 distance and steady-state speed in the 6-min walking test.

36 y Status Scale, 9-Hole Peg Test, and 25-Foot Walking Test.

37 f Bederson, rolling cylinder and ladder rung walking tests.

38 with prenatal repair also performed the 10-m walk test 1 second faster (difference in medians, 1.0; 9

39 ed greater relative improvement in the 6-min walk test (11.6 m greater, 95% CI: 10.4 to 12.8 m) and t

40 ormed better (mean [+/- SE]) on the 6-minute walk test (1507 +/- 16 vs 1349 +/- 16 ft; P<.001), mean

41 The most common tool was a timed walk test (19%); 67% reported performing >1 tool.

42 ) were identified that reported the 6-minute walk test (2 RCTs), incremental shuttle walk test (2 RCT

43 nute walk test (2 RCTs), incremental shuttle walk test (2 RCTs), or peak oxygen consumption (2 RCTs)

44 f 45; P = 0.006) and improvement in 6-minute-walk test (+20.6 m vs. -25.0 m; P = 0.017) at Day 84.

45 +40%) and endurance (mean change in 6-minute walk test: +26 m), paralleled by increased motoneuron fi

46 lass I/II (31% to 83%, p < 0.0001), 6-minute walk test (272.3 15.6 to 303.2 15.6 meters, p = 0.0023)

47 ted by increased distances during a 6-minute walk test (390 +/- 91 versus 422 +/- 86 m, P < .05) and

48 p, P=0.24) or in the results of the 6-minute walk test (397 m in the fusion group and 405 m in the de

49 capacity (47.5 m for the incremental shuttle walking test, 45-85 s for the endurance shuttle walking

50 ients underwent functional testing (6-minute walk test, 50-foot walk test, and repeated sit-to-stand

51 overy at 1 minute of rest (HRR1) after 6-min walk test (6MW test) and clinical worsening in patients

52 rformed among FSS and motor scales, 6-minute walk test (6MWT) and Hammersmiths Functional Motor Scale

53 The primary endpoint was change in 6-min walk test (6MWT) distance at 6 weeks.

54 The 6-min walk test (6MWT) distance increased in all 7 subjects at

55 scribed on the basis of a screening 6-minute walk test (6MWT) done by the front-line physical therapi

56 yperinflation, and post-rehabilitation 6-min walk test (6MWT) greater than 140 m were enrolled from 1

57 The 6-minute walk test (6MWT) independently predicts congestive heart

58 fat fraction and (1) H2 O T2 ), and 6-minute walk test (6MWT) measurements.

59 grip strength, standing long-jump, and 6-min walk test (6MWT) performance was conducted.

60 quantity of desaturation during a six-minute-walk test (6MWT) would add prognostic information to cha

61 gait (BCG), among pwMS during the six-minute walk test (6MWT), and determine their association with d

62 ionnaire-8 Summary Index (PDQ8-SI), 6-minute walk test (6MWT), and functional reach test (FRT) scores

63 Secondary endpoints included the 6-minute walk test (6MWT), KCCQ Overall Summary Score (KCCQ-OS),

64 physical performance [fast gait speed, 6 min walk test (6MWT), PROMIS score, and SF36PFS raw score] a

65 nal Independence Measure (FIM), the 6-Minute Walk Test (6MWT), the Medical Research Council (MRC) Sca

66 dergoing MitraClip (MC) underwent a 6-minute walk test (6MWT), transthoracic echocardiogram, and CMR

67 and improve distance walked on the 6-minute walk test (6MWT).

68 Patients with LAM also performed a 6-minute walk test (6MWT).

69 rcise capacity was evaluated by the 6-minute walk test (6MWT).

70 exercise capacity as documented by 6-minute walk test (6MWT).

71 al assessment in this study was the 6-Minute Walk Test (6MWT).

72 art Failure Questionnaire [MLHFQ], and 6-min walk test [6MWT]) were performed at baseline and 30 days

73 145 +/- 318; p < 0.001), as well as in 6-min walk test (81 +/- 64 m vs. -35 +/- 68 m; p < 0.001) and

74 s. -145 318; p < 0.001), as well as in 6-min walk test (81 64 m vs. -35 68 m; p < 0.001) and quality

75 ellar Functional System score, Timed 25-Foot Walk Test, 9-Hole Peg Test (9-HPT), Symbol Digit Modalit

76 knowledge of desaturation during a 6-minute walk test adds prognostic information for patients with

77 e most significant results were the 2 Minute Walk Test (adjusted mean difference 18; 95% CI 204, 222)

78 icipants, 378 (80.6%) completed the 6-minute walk test and 285 (70.1%) completed Kansas city cardiomy

79 e performed for the timed 8-foot (ie, 2.4 m) walk test and a repeated sit-to-stand test.

80 iuretic peptide and negatively with 6-minute walk test and cardiac index.

81 included exercise capacity assessed by 6-min walk test and peak VO(2), Borg dyspnea score, hemodynami

82 The patients also performed a 6-minute walk test and short-form 36-Item Health Survey questionn

83 different techniques, the 6-minute corridor walk test and the 9-minute self-powered treadmill test.

84 sociated with an improvement in the 6-minute walk test and the MLHFQ score, but neither improved exer

85 , blood test, echocardiography, and 6-minute walk test and were followed up for mortality until the e

86 tudy sites, 245 participants underwent 6-min walk tests and Mini-Mental State Examination (MMSE) at i

87 priori included resting heart rate and 6-min walk tests and/or ambulatory electrocardiographic result

88 They also performed a shuttle walking test and comprehensive lung function tests.

89 d normalized sensorimotor function in a grid-walking test and provided complete axonal protection ove

90 rmance at 6 months, assessed by the 6-minute walking test and the five times sit-to-stand test, and i

91 assessed using clinical scoring of the beam-walking test and video-kinematic analysis (CatWalk) at b

92 t, chair sit-and-reach test, and figure of 8 walk test) and activity and participation (Late Life Fun

93 Association class and results of a 6-minute walk test) and in quality of life (according to the Minn

94 om 13% to 89% of patients completing a 6-min walk test) and in quality of life (mean values improved

95 lking distance on a treadmill test, 6-minute walk test) and vascular quality of life questionnaire-6

96 chnique), cardiovascular endurance (6-minute walk test), and functional status (Fibromyalgia Impact Q

97 nt, functional capacity assessment (6-minute walk test), and symptom quantification.

98 dside" tests (ie, liver frailty index, 6-min walk test), and the more specialist investigations (ie,

99 e ability to walk 450 to 550 m on a 6-minute walk test), and were receiving optimal standard therapy,

100 atient-reported outcome measures, a 6-minute walk test, and a health economic evaluation.

101 rk Heart Association functional class, 6-min walk test, and deterioration or death.

102 George's Respiratory Questionnaire, 6-minute walk test, and imaging.

103 , in exercise capacity as evaluated by 6-min walk test, and in quality of life.

104 capacity, respiratory muscle strength, 6-min walk test, and incremental symptom-limited maximal exerc

105 ase questionnaire (CRQ), incremental shuttle walk test, and induced sputum.

106 aphy, magnetic resonance imaging, a 6-minute walk test, and measurement of natriuretic peptides befor

107 arsal diameter, functional ability on a beam walk test, and microscopic assessment of joint inflammat

108 ents included timed function tests, 6-minute walk test, and NorthStar Ambulatory Assessment (NSAA).

109 left ventricular ejection fraction, 6-minute walk test, and NT-proBNP.

110 the 6-minute walk test, incremental shuttle walk test, and peak oxygen consumption between the testo

111 inical Frailty Scale, grip strength, 5-meter walk test, and pulmonary function tests.

112 Respiratory parameters, 6-min walk test, and QOL were measured.

113 t, endurance was measured using the 6-minute walk test, and quality of life was assessed using the St

114 in the cardiopulmonary exercise test, 6-min walk test, and quality of life.

115 unit and hospital, distance on the 6-minute walk test, and quality of life.

116 York Heart Association classification, 6-min walk test, and quality-of-life scores showed progressive

117 ctional testing (6-minute walk test, 50-foot walk test, and repeated sit-to-stand test) at baseline/p

118 erformance Battery, timed up and go, a 6-min walk test, and single-leg stands.

119 ty of life questionnaire, six-minute (6-min) walk test, and sputum markers of inflammation during a 6

120 ulmonary function tests (PFTs), the 6-minute walk test, and St George Respiratory Questionnaire (SGRQ

121 line in the distance covered on the 6-minute walk test, and the change from baseline in the Kansas Ci

122 through a physical examination, the 6-Minute Walk Test, and the Functional Independence Measure Mobil

123 n functional class, ejection fraction, 6-min walk test, and the Minnesota score or its equivalent as

124 with metrics derived from PFTs, the 6-minute walk test, and the SGRQ.

125 rk Heart Association functional class, 6-min walk test, and ventricular function.

126 Research Arm Test, Ten-Meter and Six-Minute Walk Tests, and the Stroke Impact Scale.

127 king test, 45-85 s for the endurance shuttle walking test, and 46-105 s for constant-load cycling end

128 t resting cardiovascular measurements, 6-min walking tests, and cardiopulmonary exercise testing.

129 Cardiopulmonary exercise test and 6-minute walking test are frequently used tools to evaluate physi

130 City Cardiomyopathy Questionnaire, 6-minute walk test, arterial stiffness assessment, and proteomics

131 esign of future DMD trials with the 6-minute walk test as the endpoint.

132 We developed a 30 m walking test as a quantifiable measure of severity of ce

133 aseline, assessed with the use of a 6-minute walk test, as compared with placebo.

134 The results of the sit-to-stand and 2-minute walk tests, as well as the results of the maximum volunt

135 atory fitness (as measured with the 6-minute walk test), assessed at baseline and at 3, 6, 9, 12, and

136 3), was associated with an improved 6-minute walk test at 12 weeks, which was preserved over 144 week

137 rial (187 [89.0%] by completing the 6-minute walk test at 16 weeks and 10 [4.8%] by adjudication of t

138 Functional status was assessed by 6-minute walk test at 30 days, 90 days, and 1 year and PROMIS-PF-

139 improvement of at least 54 m in the 6-minute walk test at 6 months (1-sided hypothesis test).

140 operative functional walking capacity (6-min walk test) at 4 weeks after surgery.

141 et of 1096 participants performed a 6-minute walk test before FMD determination.

142 s most strongly associated with the 6-minute walk test (beta=825.3; P=0.023).

143 h biopsy-proven disease performed a 6-minute walk test between January 1996 and December 2001.

144 as no significant difference in the 6-minute walk test between the inpatient rehabilitation and eithe

145 diography, stress echocardiography, 6-minute walk test, biomarkers, and quality of life assessment (S

146 est computed tomography (CT)/X-ray, 6-minute walking test, body composition, and questionnaires on me

147 and average steady-state speed in the 6-min walking tests, both when walking with and without the AP

148 ificant motor improvement in the ladder rung walk test but not the forelimb reaching test.

149 ere was no between-group difference in 6-min walk test, but 15 IMT patients (compared with 9 placebo)

150 BFRRE improved 6-minute walk test by 39.0 m (CI, 7.0-71.1, P=0.019) compared wit

151 aged 50 years or older, underwent: 6-minute walk test (cardiopulmonary endurance), chair stands in 3

152 tervention (leg strength and power, 6-minute walk test, chair sit-and-reach test, and figure of 8 wal

153 Patients were evaluated using the 6-min walk test, changes in NYHA functional class, cardiac fun

154 The 8-foot walk test compared subjects in the lowest and highest qu

155 patients who completed a 6-minute treadmill walking test compared to those who did not, with an LOOC

156 After the group B walking test, compared with before the walking test, the

157 pose of this study was to determine if 6-min walk test data assists in treatment decisions for patien

158 ibility and Prehension (GRASSP) and the 10-m walk test decreased on average by 20% after all protocol

159 estionnaires, Timed-Stands Test, and 50-Foot Walk Test demonstrate that the HAP is a valid measure of

160 mic and metabolic assessment during 6-minute walk tests demonstrates that in patients with heart fail

161 The treadmill exercise time and the 6-min walk test did not change significantly after replacement

162 iuretic peptide concentrations, and 6-minute walking test did also not differ between groups.

163 e same pattern was observed for the 6-minute walk test distance (+125 +/- 33 m in the transendocardia

164 aire (+26 versus +31; P=0.031), and 6-minute walk test distance (+194 feet versus +340 feet; P=0.026)

165 cirrhosis had poorer performance in 6-minute walk test distance (231 vs 338 m), 30-second chair stand

166 AP) more than or equal to 14 mm Hg and 6-min walk test distance (6-MWD) less than or equal to 300 m.

167 The effects on BODE index, 6-minute-walk test distance (6MWD), and health-related quality of

168 SD 9.8] to 79.1 [13.0]; p=0.0001); and 6 min walk test distance (from a mean of 244 m [SD 112] to 318

169 erence, 6.95% [CI, 3.0% to 10.9%]), 6-minute walk test distance (mean difference, 20.93 m [CI, 5.91 t

170 seline at week 24 for all outcomes: 6-minute walk test distance (median difference, 4.9 m [95% CI, -2

171 prior hospitalizations (P < .0001), 6-minute walk test distance (P < .0001), CT RA950 relative area w

172 ng (SHR: 3.98, P = 0.002), and reduced 6-min-walk test distance (per 50 m, SHR: 1.28, P = 0.001).

173 y correlated with the change in the 6-minute walk test distance (R=0.46; P=0.014).

174 ce: -1.89 (-2.73 to -1.04) mL/kg/min], 6-min walk test distance [absolute difference: -34 (-51 to -17

175 onse relationship for the change in 6-minute walk test distance among the 5 different dose-response m

176 ncluded the change from baseline in 6-minute walk test distance and in ventilatory efficiency (ventil

177 well as a greater deterioration in 6-minute walk test distance and Kansas City Cardiomyopathy Questi

178 ith ILD, exercise training improves 6-minute walk test distance and quality of life.

179 o difference in mean (SD) change in 6-minute walk test distance between the colchicine and placebo gr

180 Groups had similar 6-minute walk test distance changes after 4 weeks (HIIT, 27 m [95

181 The primary end point was change in 6-minute walk test distance from baseline to 20 weeks (minimal cl

182 linically relevant 40-m increase in 6-minute walk test distance from baseline, an optimal dose of nel

183 Phase angle, grip strength, and 6-min walk test distance improved after heart transplantation.

184 ) significantly correlated with the 6-minute walk test distance in univariable vascular testing.

185 ore increased (mean: 43.1 to 77.0) and 6-min walk test distance results increased (mean: 163.6 to 252

186 (80% CI) increase from baseline in 6-minute walk test distance was 69 (39, 100) m (median, 47 m).

187 The 6-min walk test distance was significantly increased in the PA

188 n absolute changes from baseline in 6-minute walk test distance were 0.2 m (95% CI, -12.1 to 12.4 m)

189 and praliciguat groups, changes in 6-minute walk test distance were 58.1 m (95% CI, 26.1-90.1) and 4

190 ioverter-defibrillator, and reduced 6-minute walk test distance were randomized to ARRY-371797 400 mg

191 ge, 74 years; 160 [53%] women; mean 6-minute walk test distance, 321.5 m), 261 (86%) completed the tr

192 red peak oxygen consumption (peakVO2), 6-min walk test distance, and 36-Item Short Form Survey (SF-36

193 cal Research Council dyspnea scale, 6-minute-walk test distance, and computed tomography [CT] scan me

194 eptide/B-type natriuretic peptide, the 6-min walk test distance, and health-related quality of life i

195 well as a greater deterioration in 6-minute walk test distance, Kansas City Cardiomyopathy Questionn

196 oints included changes over time in 6-minute walk test distance, NT-proBNP (N-terminal pro-B-type nat

197 rtality, HF hospitalizations, LVEF, 6-minute walk test distance, Vo2max, and quality of life, with no

198 to treatment was assessed using the 6-minute walk test distance, which increased in 25 subjects and d

199 SFTPB (p = 0.005) were associated with 6-min walk test distance.

200 ation was stratified by country and by 6 min walk test distance.

201 d less postoperative improvement in 6-minute walking test distance (80+/-78 versus 42+/-41 m, P<0.000

202 as well as the lowest long jump and 6-minute walk test distances (P < .05).

203 d using pulmonary function testing, 6-minute-walk test, echocardiography, twitch transdiaphragmatic p

204 Gait speed was measured using the 10-meter walk test, endurance was measured using the 6-minute wal

205 and a moderate effect on fatigability (6 min walk test: ES 0.45, 95% CI -0.18 to 1.07).

206 Efficacy assessments included 6-minute walk test, exercise peak VO2, Minnesota Living with Hear

207 y Questionnaire (SGRQ), completed a 6-minute walk test for the 6-minute walk distance (6MWD), and und

208 was evaluated using the neuroscore and beam walk tests for 4 weeks postinjury (n = 11).

209 d 24 months and older then participated in a walking test for 12 minutes.

210 m baseline to week 24 and change in 6-minute walk test from baseline to week 24 is the secondary end

211 improvements in functional status and 6-min walk test (from 0% to 83% of patients in New York Heart

212 Extended walking tests have been examined as outcome predictors i

213 free mass decreased; grip strength and 6-min walk test improved after transplantation (all P < 0.001)

214 The 6-minute walk test improved more in depression remission compared

215 Six-min-walk-test improved 59.5 +/- 112.4 m, and Minnesota-livin

216 The distance covered during the 6-minute walking test improved in the exercise group (mean distan

217 onal class III/IV in 82.5%), frail (slow 5-m walk test in 81.6%), and have poor self-reported health

218 unctional assessment comprising the 6-minute walk test in ambulant individuals.

219 Effect on Exercise Capacity Using a 6-Minute Walk Test in Patients With Heart Failure), patients wore

220 d plasma nitrite abundance after a treadmill walking test in people with PAD may be associated with i

221 es were not significant, including the timed walking test in the off condition (p=0.053), the Purdue

222 t years 3 to 6, 8, and 10 and the 400-m fast walking test in years 4, 6, 8, and 10.

223 y was measured using the 20-m usual and fast walking tests in clinical visit years 3 to 6, 8, and 10

224 tolerance: The distance covered over a 6 min walk test increased from 934 +/- 297 to 1,071 +/- 241 ft

225 The 6-min walk test increased with allo-hMSCs by 37.0 m (p = 0.04)

226 The mean increase in the 6-minute walk test, incremental shuttle walk test, and peak oxyge

227 s, poor performance on treadmill or extended walking tests indicates closer proximity to future healt

228 The 6-minute walk test is used in clinical practice and clinical tria

229 , cardiopulmonary exercise testing, 6-minute walking test, isokinetic muscle function, and skeletal m

230 o-B-type natriuretic peptide level, 6-minute walk test, Kansas City Cardiac Questionnaire, and cardia

231 (using a modified Naughton protocol), 6-min walk test, left ventricular ejection fraction and dyspne

232 =80 beats/min; and maximum HR during a 6-min walk test </=110 beats/min or average HR during 24-h Hol

233 ndergoing TAVR included poor mobility (6-min walk test <50 m; hazard ratio: 1.67, p = 0.0009) and oxy

234 low exercise capacity were defined as 6-min walk test <50% predicted or use of rollator or wheelchai

235 d changes at 6 and 12 months in the 6-minute walk test, lung function, quality of life as assessed by

236 res, and 4990 (10.2%) completed the 6-minute walk test, made available only at the end of 7 days.

237 ving with Heart Failure Questionnaire, 6-min walk test, major adverse cardiac events, and immune biom

238 w during maximal handgrip exercise, 6-minute walk test, maximal oxidative capacity, and life quality;

239 symptom limited maximum exercise test, 6-min walk test, maximal static inspiratory and expiratory mou

240 h follow-up, improvements were seen in 6-min walk test (mean 21.0 m; 95% confidence interval: 1.57 to

241 0.001), and reduced distance in the 6-minute walk test (median, 488 m versus 539 m; P<0.001).

242 tus Scale, Nine Hole Peg Test, Timed 25-Foot Walk Test, Multiple Sclerosis Walking Scale-12, and Modi

243 Heart Association class III dyspnea or 6-min walk test of <330 m) at 6-month follow-up.

244 y volume in 1 second (FEV1) and the 6-minute walk test on intention-to-treat analysis.

245 self-care behavior and diet but not 6-minute walk test or 4-day step count.

246 There was no change in 6-min walk test or New York Heart Association functional class

247 ed Disability Status Scale (EDSS), 25' Timed-Walk Test, or Nine-Hole Peg Test to assess time to 3-mon

248 s associated with worse performance on timed walk test (P = 0.009, B = 0.01, 99% confidence interval

249 ressive symptoms (P=0.027), and the 6-minute walk test (P=0.012).

250 [95% CI 0.034, 0.105 event/second]; 6-minute walk test, p = 0.001 [95% CI 31.14, 93.38 meters]; North

251 Questionnaire), functional status (6-minute walk test, peak maximum oxygen consumption), biomarker (

252 g With Heart Failure Questionnaire, 6-minute walk test, peak maximum oxygen consumption, N-terminal p

253 , improvements were observed in the 6-minute walk test performance in 7 of 8 subjects, Egen Klassifik

254 block method stratified by baseline 6-minute walk test performance.

255 PPoP was associated with improved 6-minute walking test performance (328.5+/-99.9 versus 285.8+/-10

256 (muscle and/or nerve function), and 6-minute-walk test (physical function).

257 Participants completed a 400-m walk test prior to bariatric surgery (n = 206) and at 6

258 ac parameters, functional status by 6-minute walk test, quality of life according to the Kansas City

259 Secondary end points included 6-minute walk test, quality-of-life, and NT-proBNP (N-terminal pr

260 lity Status Scale (R(2)=0.26), timed 25-foot walk test (R(2)=0.23), 9-hole peg test (R(2)=0.23), Pace

261 ated with poorer performance in the 6-minute walk test (R=0.36, P=0.03).

262 4, p < 0.0001; Activity score versus shuttle walking test, r = -0.659, p < 0.0001; and impacts score

263 es also correlated with an improved 6-minute walk test result, although this correlation was weaker.

264 Six-minute walk test results and sputum analysis for cell count and

265 ssociated with improved NYHA class, 6-minute walk test results did not improve.

266 with saturation > 88% during their baseline walk test, serial decreases in FVC and increases in desa

267 The 6-min walk test (SMWT) performed in the hallway (HW) is used a

268 se-induced desaturation (during the 6-minute walk test, Spo2 >/=80% for >/=5 minutes and <90% for >/=

269 ), submaximal exercise performance (6-Minute Walk Test), standing balance (Functional Reach Test), sk

270 e indicates greater disability), and 25-Foot Walking Test (test covers 7.5 m; measured in seconds; lo

271 0.05) and shorter time to complete a narrow walk test than men who took part in only lifestyle physi

272 line in the distance covered on the 6-minute walk test than placebo (least-squares mean difference, 2

273 ercise capacity (as assessed by the 6-minute walk test) than placebo.

274 nd underwent echocardiography and a 6-minute walk test (the composite primary end point).

275 sion model to predict the patient's 6-minute walk test, the independent predictors were age (beta=-0.

276 For the 10-Meter Walk Test, the mean pre-intervention speed was 0.31 +/-

277 oup B walking test, compared with before the walking test, there was a significant increase in median

278 ly reduced muscle strength and a longer 10 m walk test time in young, ambulant patients with DMD; bot

279 provements were observed at 6 months for the walk test time to completion (mean, 376 seconds; 95% CI,

280 unctional disability scale [FDS] score, 10-m walk test time, and 9-hole peg test time) were assessed

281 ults, we administered the standardized 6-min walk test to 117 healthy men and 173 healthy women, aged

282 (hand grip strength [HGS] and Timed Up & Go walking test [TUGWT]) measures of independence were asse

283 earable metabolic cart, performed a 6-minute walking test, two 4-minute treadmill exercises (at 2 and

284 ility Status Scale (EDSS), the timed 25-foot walk test (TWT), and the nine-hole peg test.

285 A 6-min walk test utilizing a treadmill (TM) is easier to perfor

286 ds: Laboratory data, echocardiography, 6-min-walk testing, V/Q scanning, CTPA, and right heart cathet

287 tudy, no significant difference in the 6-min walk test was observed (p = 0.36, 95% CI -15.5 to 41.7).

288 imb recovery, as assessed by the ladder rung walking test, was improved at 35 dpi in rhDNase-treated

289 Participants completed a 20-m walk test wearing sensors on their trunk and ankles.

290 postprocedural quality of life and 6-minute walk test were ascertained.

291 Heart rates during the 6-minute walk test were significantly higher in the POTS group, b

292 -Item Short-Form Health Survey, and 6-minute walk test were used to assess health status.

293 Six-min walk tests were conducted at baseline, 3 weeks, 4 months

294 invasive hemodynamic measurements and 6-min walk tests were performed and outcomes prospectively fol

295 Secondary endpoints included the 6-minute walking test, where patients randomized in the SWT group

296 within reference range underwent a 2-minute walk test, which was outside reference ranges of expecte

297 An encouraged 6-minute walk test with metabolic measurements was used to assess

298 ht-sided heart catheterization, and 6-minute walk testing with a median follow-up of 4.0 years.

299 before and after iloprost inhalation, 6-min walk test, World Health Organization functional class, a

300 thesized that desaturation during a 6-minute walk test would predict mortality for patients with usua